Cooke & Bieler LP Buys 170,560 Shares of Baxter International Inc. $BAX

Cooke & Bieler LP boosted its stake in Baxter International Inc. (NYSE:BAX) by 10.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,750,510 shares of the medical instruments supplier’s stock after purchasing an additional 170,560 shares during the quarter. Cooke & Bieler LP’s holdings in Baxter International were worth $53,005,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in the stock. Creative Financial Designs Inc. ADV boosted its stake in Baxter International by 169.6% in the 2nd quarter. Creative Financial Designs Inc. ADV now owns 984 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 619 shares during the period. Oarsman Capital Inc. bought a new stake in Baxter International in the second quarter worth $213,000. Sumitomo Mitsui Trust Group Inc. boosted its holdings in Baxter International by 11.4% in the second quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,273,414 shares of the medical instruments supplier’s stock worth $38,559,000 after acquiring an additional 130,169 shares in the last quarter. RNC Capital Management LLC boosted its holdings in Baxter International by 1.7% in the second quarter. RNC Capital Management LLC now owns 138,325 shares of the medical instruments supplier’s stock worth $4,188,000 after acquiring an additional 2,277 shares in the last quarter. Finally, Whittier Trust Co. raised its stake in shares of Baxter International by 82.2% in the second quarter. Whittier Trust Co. now owns 3,202 shares of the medical instruments supplier’s stock worth $97,000 after purchasing an additional 1,445 shares during the last quarter. Institutional investors own 90.19% of the company’s stock.

Baxter International Stock Performance

NYSE:BAX opened at $18.47 on Friday. The stock has a 50-day simple moving average of $23.14 and a two-hundred day simple moving average of $26.85. Baxter International Inc. has a 52-week low of $18.42 and a 52-week high of $37.74. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.49 and a current ratio of 2.30. The firm has a market capitalization of $9.48 billion, a PE ratio of -61.55, a P/E/G ratio of 0.73 and a beta of 0.58.

Baxter International (NYSE:BAX) last released its quarterly earnings results on Thursday, October 30th. The medical instruments supplier reported $0.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.60 by $0.09. Baxter International had a positive return on equity of 16.96% and a negative net margin of 1.42%.The business had revenue of $2.84 billion during the quarter, compared to analyst estimates of $2.88 billion. During the same quarter in the previous year, the company posted $0.80 earnings per share. Baxter International’s revenue for the quarter was up 5.0% on a year-over-year basis. Baxter International has set its Q4 2025 guidance at 0.520-0.570 EPS. FY 2025 guidance at 2.350-2.400 EPS. Analysts forecast that Baxter International Inc. will post 2.48 EPS for the current year.

Wall Street Analysts Forecast Growth

BAX has been the subject of a number of research reports. Stifel Nicolaus reiterated a “hold” rating and set a $25.00 price objective (down previously from $36.00) on shares of Baxter International in a research report on Monday, August 4th. Evercore ISI reduced their price objective on Baxter International from $31.00 to $24.00 in a research report on Thursday. Wall Street Zen cut Baxter International from a “buy” rating to a “hold” rating in a research report on Saturday, August 2nd. Weiss Ratings reiterated a “sell (d)” rating on shares of Baxter International in a research report on Wednesday, October 8th. Finally, Jefferies Financial Group reduced their price objective on Baxter International from $25.00 to $21.00 and set a “hold” rating for the company in a research report on Thursday. Two investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $25.70.

About Baxter International

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.